Yoann Madec1, Faroudy Boufassa, Kholoud Porter, Maria Prins, Caroline Sabin, Antonella d'Arminio Monforte, Pauli Amornkul, Barbara Bartmeyer, Mette Sannes, Alain Venet, Olivier Lambotte, Laurence Meyer. 1. aInstitut Pasteur, Emerging Diseases Epidemiology Unit, Paris bINSERM U1018, Centre de Recherche en Epidémiologie et Santé des Populations, Le Kremlin-Bicêtre cFaculté de Médecine Paris Sud, Université Paris Sud, Paris dDepartment of Public Health, AP-HP, Bicêtre Hospital, Le Kremlin-Bicêtre, France eMedical Research Council, Clinical Trials Unit, London, UK fCluster Infectious Diseases, Department of Research, Center for Infection and Immunity Amsterdam (CINIMA), Public Health Service, Amsterdam, The Netherlands gResearch Department of Infection and Population Health, UCL Medical School, London, UK hSan Paolo Hospital, Milan, Italy iInternational AIDS Vaccine Initiative, San Francisco, USA jRobert Koch Institut, Berlin, Germany kUlleval Hospital, Oslo, Norway lINSERM U1012, Le Kremlin-Bicêtre mDepartment of Internal Medicine, AP-HP, Bicêtre Hospital, Le Kremlin-Bicêtre nUniversité Paris-Sud, Paris, France.
Abstract
OBJECTIVES: HIV-controllers spontaneously maintain HIV viremia at an undetectable level. We aimed to describe the delay to control from seroconversion, the duration of control, and risk factors for losing control. METHODS: HIV-controllers were identified from a pooled dataset of 24 seroconverter cohorts from Europe, Australia, and Canada (CASCADE). HIV-controllers had at least five consecutive viral loads less than 400/500 copies/ml, while antiretroviral therapy naive, for at least 5 years after seroconversion. End of control was defined as two consecutive viral loads above 2000 copies/ml. Duration of control was described using Kaplan-Meier estimates; factors associated with duration of control were identified using a Cox model. CD4⁺ cell count evolution during control was described using a mixed model. RESULTS: Of 9896 eligible seroconverters, we identified 140 (1.4%) HIV-controllers, the largest database of HIV-controllers followed from seroconversion. For 64 with viral load measured within 24 months from seroconversion, median delay to control was 16.7 (interquartile range: 7.8-37.9) months. Probability of maintaining control 20 years after seroconversion was 0.74 [95% confidence interval (CI): 0.64-0.85]. Occurrence of blips followed by return to undetectability did not increase the risk of loss of control [hazard ratio: 0.81 (95% CI: 0.10-6.70)]. However, CD4⁺ cell loss during control was significantly accelerated in individuals with blips. CONCLUSION: In most individuals, control occurred rapidly after seroconversion; however, more than 3 years were required to achieve control in 25% of HIV-controllers. Control may be sustained even when CD4⁺ cell levels are below 500 cells/μl, opening important new perspectives to understand the physiopathology underlying control.
OBJECTIVES: HIV-controllers spontaneously maintain HIV viremia at an undetectable level. We aimed to describe the delay to control from seroconversion, the duration of control, and risk factors for losing control. METHODS: HIV-controllers were identified from a pooled dataset of 24 seroconverter cohorts from Europe, Australia, and Canada (CASCADE). HIV-controllers had at least five consecutive viral loads less than 400/500 copies/ml, while antiretroviral therapy naive, for at least 5 years after seroconversion. End of control was defined as two consecutive viral loads above 2000 copies/ml. Duration of control was described using Kaplan-Meier estimates; factors associated with duration of control were identified using a Cox model. CD4⁺ cell count evolution during control was described using a mixed model. RESULTS: Of 9896 eligible seroconverters, we identified 140 (1.4%) HIV-controllers, the largest database of HIV-controllers followed from seroconversion. For 64 with viral load measured within 24 months from seroconversion, median delay to control was 16.7 (interquartile range: 7.8-37.9) months. Probability of maintaining control 20 years after seroconversion was 0.74 [95% confidence interval (CI): 0.64-0.85]. Occurrence of blips followed by return to undetectability did not increase the risk of loss of control [hazard ratio: 0.81 (95% CI: 0.10-6.70)]. However, CD4⁺ cell loss during control was significantly accelerated in individuals with blips. CONCLUSION: In most individuals, control occurred rapidly after seroconversion; however, more than 3 years were required to achieve control in 25% of HIV-controllers. Control may be sustained even when CD4⁺ cell levels are below 500 cells/μl, opening important new perspectives to understand the physiopathology underlying control.
Authors: Iris Chen; Vanessa Cummings; Jessica M Fogel; Mark A Marzinke; William Clarke; Matthew B Connor; Sam Griffith; Susan Buchbinder; Steven Shoptaw; Carlos Del Rio; Manya Magnus; Sharon Mannheimer; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Trevor A Crowell; Kelly A Gebo; Joel N Blankson; P Todd Korthuis; Baligh R Yehia; Richard M Rutstein; Richard D Moore; Victoria Sharp; Ank E Nijhawan; W Christopher Mathews; Lawrence H Hanau; Roberto B Corales; Robert Beil; Charurut Somboonwit; Howard Edelstein; Sara L Allen; Stephen A Berry Journal: J Infect Dis Date: 2014-12-15 Impact factor: 5.226
Authors: Steven G Deeks; Nancie Archin; Paula Cannon; Simon Collins; R Brad Jones; Marein A W P de Jong; Olivier Lambotte; Rosanne Lamplough; Thumbi Ndung'u; Jeremy Sugarman; Caroline T Tiemessen; Linos Vandekerckhove; Sharon R Lewin Journal: Nat Med Date: 2021-12-01 Impact factor: 53.440
Authors: David R Collins; Jonathan M Urbach; Zachary J Racenet; Umar Arshad; Karen A Power; Ruchi M Newman; Geetha H Mylvaganam; Ngoc L Ly; Xiaodong Lian; Anna Rull; Yelizaveta Rassadkina; Adrienne G Yanez; Michael J Peluso; Steven G Deeks; Francesc Vidal; Mathias Lichterfeld; Xu G Yu; Gaurav D Gaiha; Todd M Allen; Bruce D Walker Journal: Immunity Date: 2021-09-07 Impact factor: 43.474
Authors: Peter Zuidewind; Mark Cotton; Shaun Barnabas; Anita Janse Van Rensburg; Gert van Zyl; Carli Gordijn Journal: S Afr J Infect Dis Date: 2022-06-30